Comparable Liraglutide Pharmacokinetics in Pediatric and Adult Populations with Type 2 Diabetes: A Population Pharmacokinetic Analysis

Clinical Pharmacokinetics

Volumn 54, Issue 6, 2015, Pages 663-670

  Petri, Kristin C Carlsson ^a   Jacobsen, Lisbeth V ^a   Klein, David J ^b  

^a NOVO NORDISK A S   (Denmark)

^b Medpace ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN DETEMIR; LIRAGLUTIDE; METFORMIN; PLACEBO; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADOLESCENT; ADULT; ADULT DISEASE; AGE DISTRIBUTION; AGED; AREA UNDER THE CURVE; ARTICLE; BLINDNESS; BODY WEIGHT; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CREATININE CLEARANCE; CROSSOVER PROCEDURE; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; STEADY STATE; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; BODY WEIGHT; CHILD; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; SEX FACTORS;

EID: 84930084869     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0229-z     Document Type: Article

References (25)

1. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009;32:1224–30.
2. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009;52:2046–55.
3. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84–90.
4. Marre M, Shaw J, Brandle M, Bebakar WM, Kamaruddin NA, Strand J, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268–78.
5. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473–81.
6. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39–47.
7. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375:1447–56.
8. Ingwersen SH, Khurana M, Madabushi R, Watson E, Jonker DM, Le Thi TD, et al. Dosing rationale for liraglutide in type 2 diabetes mellitus: a pharmacometric assessment. J Clin Pharmacol. 2012;52:1815–23.
9. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr. 2005;146:693–700.
10. Vaidyanathan J, Choe S, Sahajwalla CG. Type 2 diabetes in pediatrics and adults: thoughts from a clinical pharmacology perspective. J Pharm Sci. 2012;101:1659–71.
11. Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366:2247–56.
12. Klein DJ, Battelino T, Chatterjee DJ, Hale PM, Chang CT, Arslanian SA. Liraglutide trial in pediatric type 2 diabetes: safety, tolerability and pharmacokinetics/pharmacodynamics. Diabetes Technol Ther. 2014;16(10):679–8.
13. De Cock RF, Piana C, Krekels EH, Danhof M, Allegaert K, Knibbe CA. The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol. 2011;67(Suppl 1):5–16.
14. Hermansen K, Baekdal TA, During M, Pietraszek A, Mortensen LS, Jorgensen H, et al. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, crossover trial. Diabetes Obes Metab. 2013;15(11):1040–8.
15. Morrow L, Hompesch M, Guthrie H, Chang D, Chatterjee DJ. Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction. Diabetes Obes Metab. 2011;13:75–80.
16. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Last amended by the 59th WMA General Assembly, Seoul. 2008. http://www.wma.net/en/30publications/10policies/b3/.
17. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline: Guideline For Good Clinical Practice E6 (R1), current Step 4 version, dated 10 June 1996. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf.
18. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002;45:195–202.
19. US Food and Drug Administration. Guidance for industry: general considerations for pediatric pharmacokinetic studies for drugs and biological products. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072114.pdf. Accessed 30 May 2013.
20. Hu C, Zhang J, Zhou H. Confirmatory analysis for phase III population pharmacokinetics. Pharm Stat. 2011;10:14–26.
21. Knebel W, Tammara B, Udata C, Comer G, Gastonguay MR, Meng X. Population pharmacokinetic modeling of pantoprazole in pediatric patients from birth to 16 years. J Clin Pharmacol. 2011;51:333–45.
22. Gottschalk M, Danne T, Vlajnic A, Cara JF. Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study. Diabetes Care. 2007;30:790–4.
23. Al-Shareef MA, Sanneh AF, Aljoudi AS. Clinical effect of metformin in children and adolescents with type 2 diabetes mellitus: a systematic review and meta-analysis. J Family Community Med. 2012;19:68–73.
24. Liese AD, D’Agostino RB Jr, Hamman RF, Kilgo PD, Lawrence JM, Liu LL, et al. The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics. 2006;118:1510–8.
25. European Medicines Agency. Guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003066.pdf. Accessed 16 Aug 2013.